Author:
Wang Stephani C.,Nichols Elizabeth L.,Farkouh Michael E.,Sidhu Mandeep S.
Publisher
Springer International Publishing
Reference39 articles.
1. Akerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Buck K, et al. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the platelet inhibition and patient outcomes study. Clin Chem. 2012;58(1):190–9.
2. Chu CY, Lin TH, Lai WT. The management and prognostic factors of acute coronary syndrome: evidence from the Taiwan acute coronary syndrome full Spectrum registry. Acta Cardiol Sin. 2017;33(4):329–38.
3. Mathew RO, Bangalore S, Lavelle MP, Pellikka PA, Sidhu MS, Boden WE, et al. Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney Int. 2017;91(4):797–807.
4. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.
5. Washam JB, Herzog CA, Beitelshees AL, Cohen MG, Henry TD, Kapur NK, et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation. 2015;131(12):1123–49.